

Clifton Road NE, Mailstop H24-8,
Atlanta, Georgia 30329-4027.
Telephone: (404) 639-8836; Email:
ACIP@cdc.gov.

SUPPLEMENTARY INFORMATION: *Purpose:* The Advisory Committee on Immunization Practices (ACIP) is charged with advising the Director, Centers for Disease Control and Prevention (CDC), on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under applicable provisions of the Affordable Care Act and Section 2713 of the Public Health Service Act, immunization recommendations of ACIP that have been approved by the Director, CDC, and appear on CDC immunization schedules generally must be covered by applicable health plans.

Matters to be Considered: The agenda will include discussions of maternal respiratory syncytial virus (RSV) vaccine. A recommendation vote for maternal RSV vaccine is scheduled. A Vaccines for Children vote is scheduled for maternal RSV vaccine. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit <https://www.cdc.gov/vaccines/acip/meetings/index.html>.

Meeting Information: The meeting will be webcast live via the World Wide Web. For more information on ACIP, please visit the ACIP website: <https://www.cdc.gov/vaccines/acip/index.html>.

Public Participation

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on <https://www.regulations.gov>. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social

Security numbers, medical information, inappropriate language, or duplicate/near-duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket.

Written Public Comment: The docket will be opened to receive written comments on September 7, 2023. Written comments must be received by September 21, 2023.

Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below.

Procedure for Oral Public Comment: All persons interested in making an oral public comment at the September 22, 2023, ACIP meeting must submit a request between September 7, 2023, and September 20, 2023, at <https://www.cdc.gov/vaccines/acip/meetings/index.html> no later than 11:59 p.m., EDT, September 20, 2023, according to the instructions provided.

If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email on September 21, 2023. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to three minutes, and each speaker may only speak once per meeting.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-19135 Filed 9-5-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Lead Exposure and Prevention Advisory Committee

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Lead Exposure and Prevention Advisory Committee (LEPAC). This is a hybrid meeting which will occur in person and online and is open to the public. Advance registration by September 29, 2023, is needed to receive the information to attend the meeting. The registration link is provided in the addresses section below.

DATES: The meeting will be held on October 16, 2023, from 9 a.m. to 4:30 p.m., EDT and October 17, 2023, from 9 a.m. to 1 p.m., EDT.

ADDRESSES: Register in advance at <https://forms.office.com/pages/responsepage.aspx?id=eCgFR53Gc0uxesXQDXVjuPeyypfKOR5Gj2Gz6aPXBGpUREZISTBGVjczTFILRU5NUjY0SFNaQTM0UC4u&web=1&wdLOR=c61C32E80-28BF-40D7-AC2D-E113AEFDAA23> to receive information to attend the meeting.

FOR FURTHER INFORMATION CONTACT: Paul Allwood, Ph.D., M.P.H., Designated Federal Officer, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta, Georgia 30341, Telephone: 770-488-6774; Email: LEPAC@cdc.gov.

SUPPLEMENTARY INFORMATION:

Background: The Lead Exposure and Prevention Advisory Committee was established under Section 2203 of Public Law 114-322, the Water Infrastructure Improvements for the Nation Act; 42 U.S.C. 300j-21, Registry for Lead Exposure and Prevention Advisory Committee.

Purpose: The LEPAC is charged with providing advice and guidance to the Secretary, Department of Health and Human Services (HHS), and the Director, CDC and Administrator, ATSDR, on (1) reviewing Federal programs and services available to individual communities exposed to lead; (2) reviewing current research on lead exposure to identify additional

research needs; (3) reviewing and identifying best practices, or the need for best practices regarding lead screening and the prevention of lead poisoning; (4) identifying effective services, including services relating to healthcare, education, and nutrition for individuals and communities affected by lead exposure and lead poisoning, including in consultation with, as appropriate, the lead exposure registry as established in section 2203(b) of Public Law 114–322; and (5) undertaking any other review or activities that the Secretary determines to be appropriate.

Matters To Be Considered: The agenda will include presentations on the following topics: aligning HUD inspection protocols for assisted housing for the last 20 years, the environmental factors impacting lead reduction, EPA's proposal on lead dust clearance level and hazard standard, updates on blood lead testing instrument, lead related funding opportunities for community-based organizations, state policy actions related to the blood lead reference value, CDC's efforts to increase blood lead testing in children enrolled in Medicaid, and an update from the Preventing Lead Exposure in Adults workgroup. Agenda items are subject to change as priorities dictate.

Public Participation

Oral Public Comment: The public comment period is scheduled on October 16, 2023, from 1:30 p.m. until 2 p.m., and October 17, 2023, from 9:15 a.m. until 9:45 a.m. EDT. Individuals wishing to make a comment during the public comment period, please email your name, organization, and phone number by October 1, 2023, to LEPAC@cdc.gov.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023–19134 Filed 9–5–23; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Meeting of the Community Preventive Services Task Force (CPSTF)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: The Centers for Disease Control and Prevention, within the Department of Health and Human Services, announces the next meeting of the Community Preventive Services Task Force (CPSTF) on October 18–19, 2023.

DATES: The meeting will be held on Wednesday, October 18, 2023, from 9:00 a.m. to 5:00 p.m. EDT, and Thursday, October 19, 2023, from 9:00 a.m. to 5:00 p.m. EDT.

ADDRESSES: The meeting will be available to the public via web conference.

FOR FURTHER INFORMATION CONTACT:

Kenya Turner, Office of Science, Office of Scientific Evidence and Recommendations, Community Guide Program; Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS–H21–10, Atlanta, GA 30329. Telephone: (404) 718–4592; Email: CPSTF@cdc.gov.

SUPPLEMENTARY INFORMATION:

Meeting Accessibility: The CPSTF meeting will be shown via web conference.

All meeting attendees must register by October 11, 2023. CDC will email web conference login information and the agenda to registrants from the CPSTF@cdc.gov mailbox approximately two weeks before the meeting start date.

To register for the meeting, individuals should send an email to CPSTF@cdc.gov and include the following information: name, title, organization name, organization address, phone, and email.

Public Comment: Individuals who would like to make public comments during the October meeting must state their desire to do so in an email to the CPSTF@cdc.gov mailbox no later than October 11, 2023. The request should include name, organizational affiliation, and topic to be addressed. Public comment must be relevant to one of the topics proposed for the meeting. The requestor will receive instructions related to the public comment process for this meeting after the request is received. A public comment period

follows the CPSTF's discussion of each systematic review and will be limited to no more than three minutes per person. Public comments may be used to inform task force discussions and will be included in the meeting summary.

Background on the CPSTF: The CPSTF is an independent, nonfederal panel whose members are appointed by the CDC Director. CPSTF members represent a broad range of research, practice, and policy expertise in prevention, wellness, health promotion, and public health. The CPSTF was convened in 1996 by HHS to identify community preventive programs, services, and policies that increase health and longevity, save lives and dollars, and improve Americans' quality of life. CDC is mandated to provide ongoing administrative, research, and technical support for the operations of the CPSTF. During its meetings, the CPSTF considers the findings of systematic reviews of existing research and practice-based evidence, and issues recommendations. CPSTF recommendations are not mandates for compliance or spending. Instead, they provide information about evidence-based options that decision makers and affected community members can consider when they are determining what best meets the specific needs, preferences, available resources, and constraints of their jurisdictions and constituents. The CPSTF's recommendations, along with the systematic reviews of the evidence on which they are based, are compiled on the Community Guide website (www.thecommunityguide.org).

Matters proposed for discussion: The agenda will consist of deliberation on systematic reviews of literature. Topics proposed for the October 2023 meeting include cancer, preparedness and response, social determinants of health, and substance use. Changes regarding the start and end times for each day, and any updates to agenda topics, will be available on the Community Guide website (www.thecommunityguide.org) closer to the date of the meeting. The meeting agenda is subject to change without notice.

Tiffany Brown,

Executive Secretary, Centers for Disease Control and Prevention.

[FR Doc. 2023–19150 Filed 9–5–23; 8:45 am]

BILLING CODE 4163–18–P